Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AIM ImmunoTech Inc. AIM
$0.44
-$0.01 (-2.11%)
На 17:16, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
22267358.00000000
-
week52high
1.05
-
week52low
0.29
-
Revenue
141000
-
P/E TTM
-1174
-
Beta
-0.29896100
-
EPS
-0.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | Hold | 10 окт 2019 г. |
| Maxim Group | Hold | Buy | 22 авг 2019 г. |
| Maxim Group | Buy | Buy | 14 июн 2019 г. |
| Chardan Capital | Buy | Buy | 21 янв 2014 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Equels Thomas K | A | 543995 | 161291 | 03 янв 2023 г. |
| APPELROUTH STEWART | A | 217063 | 80646 | 03 янв 2023 г. |
| Rodino Peter W III | A | 143839 | 80646 | 03 янв 2023 г. |
| MITCHELL WILLIAM M | A | 50000 | 50000 | 30 ноя 2022 г. |
| Rodino Peter W III | A | 100000 | 100000 | 30 ноя 2022 г. |
| APPELROUTH STEWART | A | 50000 | 50000 | 30 ноя 2022 г. |
| Equels Thomas K | A | 300000 | 300000 | 30 ноя 2022 г. |
| Equels Thomas K | A | 382704 | 32895 | 18 июл 2022 г. |
| APPELROUTH STEWART | A | 136417 | 24500 | 25 апр 2022 г. |
| Rodino Peter W III | A | 63193 | 4902 | 25 апр 2022 г. |
Новостная лента
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
GlobeNewsWire
09 мая 2023 г. в 08:50
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced today that management will host a conference call and webcast to discuss the Company's Q1 2023 operational and financial results on Tuesday, May 16, 2023 at 8:30 AM ET.
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
GlobeNewsWire
27 мар 2023 г. в 09:05
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET.
AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center
Proactive Investors
17 янв 2023 г. в 10:26
AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands that will evaluate the potential of AIM's Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancer. Ampligen is AIM's dsRNA drug currently being developed for globally important cancers.
5 Penny Stocks To Watch After Big News This Week
PennyStocks
17 янв 2023 г. в 09:24
Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent
Proactive Investors
09 янв 2023 г. в 09:25
AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candidate Ampligen (rintatolimod), which claims cover, among other aspects, compositions, and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM's existing portfolio for COVID-19 treatments to include rugged dsRNA, the company said.